Ar­cus de­pri­or­i­tizes Gilead-part­nered drug in prostate can­cer, the lat­est hic­cup in $1.6B col­lab­o­ra­tion

Ar­cus Bio­sciences is re­duc­ing fur­ther in­vest­ment on its adeno­sine re­cep­tor an­tag­o­nist in prostate can­cer af­ter re­view­ing in­ter­im da­ta, ac­cord­ing to its sec­ond quar­ter re­port. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER